<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85338">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01994252</url>
  </required_header>
  <id_info>
    <org_study_id>RN00208414</org_study_id>
    <nct_id>NCT01994252</nct_id>
  </id_info>
  <brief_title>Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation</brief_title>
  <acronym>RAFT-PermAF</acronym>
  <official_title>Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) and heart failure (HF) are two common heart conditions that are
      encountered with an increase in death and suffering. When both these two conditions occur in
      a patient, the patient's prognosis is poor with a reduced quality of life. These patients
      are frequently admitted to the hospital and have increased risk of death. In these HF
      patients who are in AF all of the time, who would otherwise be a suitable candidate for an
      implantable defibrillator to prevent sudden cardiac death, whether adding pacing of both
      ventricles will reduce death and suffering. Other studies have shown that adding pacing to
      both ventricles is of benefit in HF patients with mild to moderate symptoms and have a
      regular heart rhythm. The Investigators now want to explore if this therapy will benefit
      those patients with a permanent irregular heart rhythm (AF). The Investigators will also be
      assessing the cost effectiveness of this treatment strategy and the life quality for these
      patients. This study may have a dramatic impact on the way the Investigators manage these
      patients with atrial fibrillation and heart failure and may improve the outlook and well
      being of these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is increasing in prevalence and incidence, and is the most common reason
      for hospital admissions of patients over the age of 65. Therapy for HF has evolved over the
      last two decades. Cardiac resynchronization therapy (CRT) is a therapy that attempts to
      resynchronize the sequence of ventricular contraction in heart failure (HF) patients with
      left ventricular (LV) systolic dysfunction and ventricular dyssynchrony. CRT is achieved by
      stimulating both RV and LV together, synchronized to right atrial excitation to achieve
      atrio-ventricular synchrony. Clinical trials have demonstrated that CRT improved survival
      and reduced HF hospitalization in mild to advanced HF patients. In addition, CRT reversed
      the remodeling process such that it was associated with a reduction of LV size, and an
      increase of LV ejection fraction (EF). This knowledge translated to a change in practice
      guidelines and the adoption of CRT into clinical practice benefitting many HF patients CRT
      is now an important state-of-the-art therapy for HF patients with LV systolic dysfunction,
      low LVEF, and prolonged QRS duration in sinus rhythm, since the vast majority of the CRT
      clinical research was performed in patients in sinus rhythm. However, in the ~25% of HF
      patients with permanent atrial fibrillation (AF), the effectiveness of CRT is not clear. It
      is therefore timely to address the question of whether the addition of CRT to optimal HF
      treatment, rate control and an ICD is beneficial to reduce all-cause mortality or HF
      hospitalization in HF patients in permanent AF with LV systolic dysfunction and prolonged
      QRS duration

      Objectives: to determine whether cardiac resynchronization therapy will reduce all-cause
      mortality or hospitalization for heart failure in patients with permanent atrial
      fibrillation, mild to moderate heart failure, left ventricular systolic dysfunction, and
      prolonged QRS duration, when compared to implantable cardioverter defibrillator (ICD)
      therapy alone

      Methods: This is a multi-centre randomized controlled trial of two treatment groups. The
      patients, primary physicians and the heart failure caregivers will be blinded to the
      treatment allocation. The device follow-up caregivers will not be blinded. Patients with
      NYHA Class II and III HF symptoms, LVEF HF ≤ 35% , permanent AF, on optimal medical therapy
      and QRS durations ≥ 130 ms when the QRS morphology is LBBB, or QRS durations ≥ 150 ms when
      the QRS morphology is non-LBBB, or Paced QRS will be included in the trial. Patients should
      be suitable candidates for either of the 2 treatment strategies. There will be 950 patients
      randomized in 1:1 ratio to two groups: 1) ICD-CRT, 2) ICD only. All patients will undergo
      baseline clinical evaluation, quality of life assessment, medication assessment, blood
      chemistry including liver, renal, thyroid, and NT-proBNP. The patients will be followed at 1
      month, 3 months, 6 months and then every 6 months. A history and physical examination will
      be performed at baseline and at follow-up visits. Blood work, quality of life assessment,
      and 6-minute walk distance will also be performed at baseline and at follow-up visits. The
      Investigators anticipate that this study will have a major impact on how HF patients in
      permanent AF with LV systolic dysfunction and prolonged QRS duration will be treated in the
      future.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is a composite of all-cause mortality and hospitalization for HF.</measure>
    <time_frame>41/2 year study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>41/2 year study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for Heart Failure</measure>
    <time_frame>41/2 year study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>41/2 year study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>41/2 year study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measures</measure>
    <time_frame>41/2 year study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute walk distance</measure>
    <time_frame>41/2 year study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular hospitalizations</measure>
    <time_frame>41/2 year study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Heart Disease</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Optimal Medical therapy plus ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter only group will receive an ICD + optimal medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical therapy plus CRT/ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter plus cardiac resynchronisation therapy (CRT) group will receive an ICD + CRT and optimal medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimal Medical therapy plus ICD</intervention_name>
    <arm_group_label>Optimal Medical therapy plus ICD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimal Medical therapy plus CRT/ICD</intervention_name>
    <arm_group_label>Optimal Medical therapy plus CRT/ICD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with NYHA Class II or III HF symptoms (assessment in the last 3 months)

          -  Permanent AF

          -  Optimal Medical Therapy for HF of at least 3 months (according to 2009 ACCF/AHA and
             ESC 2012 recommendations,)

          -  LVEF ≤ 35% (assessment in the last 6 months)

          -  Candidacy for an ICD for primary or secondary prevention of sudden cardiac death

          -  QRS durations ≥ 130 ms when the QRS morphology is LBBB, or QRS durations ≥ 150 ms
             when the QRS morphology is non-LBBB or Paced QRS

        Exclusion Criteria:

          -  In-hospital patients who have acute cardiac or non-cardiac illness that requires
             intensive care

          -  Intra-venous inotropic agent in the last 4 days

          -  Patients with a life expectancy of less than one year from non-cardiac cause.

          -  Expected to undergo cardiac transplantation within one year (status I)

          -  Acute coronary syndrome (including MI) &lt; 4 weeks

          -  Unable or unwilling to provide informed consent

          -  Uncorrected or uncorrectable primary valvular disease

          -  Restrictive, hypertrophic or reversible form of cardiomyopathy

          -  Severe primary pulmonary disease such as cor pulmonale

          -  Tricuspid prosthetic valve

          -  Patients included in other clinical trial that will affect the objectives of this
             study

          -  Coronary revascularization (CABG or PCI) &lt; 3 months

          -  Patients with an existing ICD or CRT pacemaker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony SL Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony SL Tang, MD</last_name>
    <phone>519-663-3746</phone>
    <email>anthonysltang@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>George A Wells, PhD</last_name>
    <phone>613-761-8640</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Libin Cardiovascular Institute of Alberta</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steven Wilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mazankowski Alberta Heart Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roopinder Sandhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stanley TUng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Matthew Bennett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Novak, MD</last_name>
      <phone>250-595-0400</phone>
    </contact>
    <investigator>
      <last_name>Paul Novak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Colette Seifer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Science</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ratika Parkash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeff Healey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Damian Redfearn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Yee, MD</last_name>
      <phone>519-663-3746</phone>
      <email>ryee@uwo.ca</email>
    </contact>
    <investigator>
      <last_name>Peter Leong-Sit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1W 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David H Birnie, MD</last_name>
      <phone>613-761-4705</phone>
      <email>dbirnie@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>David H. Birnie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Angaran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eugene Crystal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital,</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew Ha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill Health Science Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vidal Essebag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernard Thibault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM Centre hospitalier universitaire de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benoit Coutu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Cœur de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marcio Sturmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>François Philippon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Ayala-Paredes, MD</last_name>
      <email>felix.ayala-paredes@usherbrooke.ca</email>
    </contact>
    <investigator>
      <last_name>Felix Ayala-Paredes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regina General Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Omar Sultan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators.. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010 Dec 16;363(25):2385-95. doi: 10.1056/NEJMoa1009540. Epub 2010 Nov 14.</citation>
    <PMID>21073365</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 14, 2016</lastchanged_date>
  <firstreceived_date>November 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>defibrillator</keyword>
  <keyword>cardiac resynchronization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
